[KLK] YoY Annual (Unaudited) Result on 30-Sep-2019 [#4]

Announcement Date
19-Nov-2019
Admission Sponsor
-
Sponsor
-
Financial Year
30-Sep-2019
Quarter
30-Sep-2019 [#4]
Profit Trend
YoY- -18.03%
View:
Show?
Annual (Unaudited) Result
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
Revenue 27,149,474 19,915,796 15,595,956 15,533,887 18,400,500 21,004,036 16,505,810 8.64%
PBT 3,219,478 2,976,425 1,185,730 823,928 1,117,380 1,450,205 1,712,284 11.09%
Tax -781,121 -524,373 -328,681 -173,195 -313,276 -383,329 -29,144 72.94%
NP 2,438,357 2,452,052 857,049 650,733 804,104 1,066,876 1,683,140 6.36%
-
NP to SH 2,166,290 2,257,584 772,604 617,505 753,328 1,005,130 1,592,191 5.26%
-
Tax Rate 24.26% 17.62% 27.72% 21.02% 28.04% 26.43% 1.70% -
Total Cost 24,711,117 17,463,744 14,738,907 14,883,154 17,596,396 19,937,160 14,822,670 8.88%
-
Net Worth 14,285,568 11,858,689 10,827,926 10,362,115 11,427,081 11,576,176 10,447,313 5.35%
Dividend
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
Div 215,631 215,612 161,771 159,744 159,744 532,482 532,482 -13.98%
Div Payout % 9.95% 9.55% 20.94% 25.87% 21.21% 52.98% 33.44% -
Equity
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
Net Worth 14,285,568 11,858,689 10,827,926 10,362,115 11,427,081 11,576,176 10,447,313 5.35%
NOSH 1,081,017 1,081,017 1,081,017 1,064,965 1,064,965 1,064,965 1,064,965 0.24%
Ratio Analysis
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
NP Margin 8.98% 12.31% 5.50% 4.19% 4.37% 5.08% 10.20% -
ROE 15.16% 19.04% 7.14% 5.96% 6.59% 8.68% 15.24% -
Per Share
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
RPS 2,518.14 1,847.37 1,446.11 1,458.63 1,727.80 1,972.27 1,549.89 8.42%
EPS 200.90 209.30 72.00 58.00 70.70 94.40 149.50 5.04%
DPS 20.00 20.00 15.00 15.00 15.00 50.00 50.00 -14.15%
NAPS 13.25 11.00 10.04 9.73 10.73 10.87 9.81 5.13%
Adjusted Per Share Value based on latest NOSH - 1,064,965
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
RPS 2,407.58 1,766.11 1,383.03 1,377.52 1,631.73 1,862.61 1,463.71 8.64%
EPS 192.10 200.20 68.51 54.76 66.80 89.13 141.19 5.26%
DPS 19.12 19.12 14.35 14.17 14.17 47.22 47.22 -13.98%
NAPS 12.6683 10.5161 9.6021 9.189 10.1334 10.2656 9.2645 5.35%
Price Multiplier on Financial Quarter End Date
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
Date 30/09/22 30/09/21 30/09/20 30/09/19 28/09/18 29/09/17 30/09/16 -
Price 20.70 20.12 22.80 23.08 24.96 24.56 23.98 -
P/RPS 0.82 1.09 1.58 1.58 1.44 1.25 1.55 -10.06%
P/EPS 10.30 9.61 31.83 39.80 35.29 26.02 16.04 -7.11%
EY 9.71 10.41 3.14 2.51 2.83 3.84 6.23 7.67%
DY 0.97 0.99 0.66 0.65 0.60 2.04 2.09 -12.00%
P/NAPS 1.56 1.83 2.27 2.37 2.33 2.26 2.44 -7.18%
Price Multiplier on Announcement Date
30/09/22 30/09/21 30/09/20 30/09/19 30/09/18 30/09/17 30/09/16 CAGR
Date 23/11/22 23/11/21 18/11/20 19/11/19 14/11/18 22/11/17 16/11/16 -
Price 21.20 20.26 23.32 22.50 24.92 24.50 23.92 -
P/RPS 0.84 1.10 1.61 1.54 1.44 1.24 1.54 -9.60%
P/EPS 10.55 9.67 32.55 38.80 35.23 25.96 16.00 -6.70%
EY 9.48 10.34 3.07 2.58 2.84 3.85 6.25 7.18%
DY 0.94 0.99 0.64 0.67 0.60 2.04 2.09 -12.46%
P/NAPS 1.60 1.84 2.32 2.31 2.32 2.25 2.44 -6.78%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment